Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can your own blood help restore lost sight?

NCT ID NCT07330713

Disease control Sponsor: Uludag University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether injecting a person's own concentrated platelets (PRP) around the eye could help treat a sudden loss of vision caused by poor blood flow to the optic nerve. 31 adults with this condition were randomly assigned to receive either PRP injections or just observation. The researchers measured changes in vision and nerve health over 16 weeks to see if the treatment was safe and effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

31 people

The number who actually took part.

Started

Jan 2022

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of acute non-arteritic anterior ischemic optic neuropathy (NAION) based on clinical history and ophthalmologic examination Acute, painless vision loss and/or visual field defect Symptom onset within 14 days prior to enrollment Age 40 years or older Ability to cooperate with best-corrected visual acuity and visual field examinations Willingness and ability to complete all follow-up visits (weeks 1, 3, 6, 8, and 16) Provision of written informed consent Exclusion Criteria: * Arteritic anterior ischemic optic neuropathy Posterior ischemic optic neuropathy Age under 40 years Presence of concomitant ocular diseases that could affect visual outcomes (e.g., glaucoma, diabetic macular edema, retinal dystrophy) Presence of neurological diseases that may affect the optic nerve (e.g., demyelinating disease, intracranial or intraorbital mass) Inability to cooperate with visual acuity or visual field testing Presence of systemic hematological disorders that could interfere with platelet-rich plasma preparation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nonarteritic anterior ischemic optic neuropathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anterior ischemic optic neuropathy non-arteritic anterior ischemic optic neuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nonarteritic anterior ischemic optic neuropathy

Contacts and locations

Locations

  • Uludag University, Department of Ophthalmology

    Bursa, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.